Vavricka John has filed 17 insider transactions across 1 company since January 2023.
Most recent transaction: a grant/award of 119520 shares of Atea Pharmaceuticals, Inc. ($AVIR) on January 31, 2026.
Activity breakdown: 0 open-market purchases and 1 sale.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 31, 2026 | Atea Pharmaceuticals, Inc. | $AVIR | Vavricka John | Chief Commercial Officer | A | Stock Option (Right to Buy) | 119520 | $0.00 | 119,520.0000 | 78,126,796 | 9999.99% | 0.15% |
| Jan. 31, 2026 | Atea Pharmaceuticals, Inc. | $AVIR | Vavricka John | Chief Commercial Officer | M | Restricted Stock Units | 8750 | $0.00 | 0.0000 | 78,126,796 | 100.00% | 0.01% |
| Jan. 31, 2026 | Atea Pharmaceuticals, Inc. | $AVIR | Vavricka John | Chief Commercial Officer | M | Restricted Stock Units | 33333 | $0.00 | 0.0000 | 78,126,796 | 100.00% | 0.04% |
| Jan. 31, 2026 | Atea Pharmaceuticals, Inc. | $AVIR | Vavricka John | Chief Commercial Officer | F | Common Stock | 11570 | $4.24 | 165,102.0000 | 78,126,796 | 6.55% | 0.01% |
| Jan. 31, 2026 | Atea Pharmaceuticals, Inc. | $AVIR | Vavricka John | Chief Commercial Officer | M | Common Stock | 42083 | $0.00 | 176,672.0000 | 78,126,796 | 31.27% | 0.05% |
| Jan. 31, 2025 | Atea Pharmaceuticals, Inc. | $AVIR | Vavricka John | Chief Commercial Officer | A | Stock Option (Right to Buy) | 132800 | $0.00 | 132,800.0000 | 0 | 9999.99% | 0.00% |
| Jan. 31, 2025 | Atea Pharmaceuticals, Inc. | $AVIR | Vavricka John | Chief Commercial Officer | M | Common Stock | 33333 | $0.00 | 137,356.0000 | 0 | 32.04% | 0.00% |
| Jan. 31, 2025 | Atea Pharmaceuticals, Inc. | $AVIR | Vavricka John | Chief Commercial Officer | A | Common Stock | 8750 | $0.00 | 146,106.0000 | 0 | 6.37% | 0.00% |
| Jan. 31, 2025 | Atea Pharmaceuticals, Inc. | $AVIR | Vavricka John | Chief Commercial Officer | F | Common Stock | 11517 | $3.06 | 134,589.0000 | 0 | 7.88% | 0.00% |
| Jan. 31, 2025 | Atea Pharmaceuticals, Inc. | $AVIR | Vavricka John | Chief Commercial Officer | M | Restricted Stock Units | 33333 | $0.00 | 33,333.0000 | 0 | 50.00% | 0.00% |
| Jan. 31, 2025 | Atea Pharmaceuticals, Inc. | $AVIR | Vavricka John | Chief Commercial Officer | A | Restricted Stock Units | 8750 | $0.00 | 8,750.0000 | 0 | 9999.99% | 0.00% |
| Jan. 31, 2024 | Atea Pharmaceuticals, Inc. | $AVIR | Vavricka John | Chief Commercial Officer | A | Stock Option (Right to Buy) | 132800 | $0.00 | 132,800.0000 | 0 | 9999.99% | 0.00% |
| Jan. 31, 2024 | Atea Pharmaceuticals, Inc. | $AVIR | Vavricka John | Chief Commercial Officer | M | Restricted Stock Units | 33334 | $0.00 | 66,666.0000 | 0 | 33.33% | 0.00% |
| Feb. 1, 2024 | Atea Pharmaceuticals, Inc. | $AVIR | Vavricka John | Chief Commercial Officer | S | Common Stock | 11819 | $3.84 | 104,023.0000 | 0 | 10.20% | 0.00% |
| Jan. 31, 2024 | Atea Pharmaceuticals, Inc. | $AVIR | Vavricka John | Chief Commercial Officer | M | Common Stock | 33334 | $0.00 | 115,842.0000 | 0 | 40.40% | 0.00% |
| Jan. 31, 2023 | Atea Pharmaceuticals, Inc. | $AVIR | Vavricka John | Chief Commercial Officer | A | Stock Option (Right to Buy) | 140000 | $0.00 | 140,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 31, 2023 | Atea Pharmaceuticals, Inc. | $AVIR | Vavricka John | Chief Commercial Officer | A | Restricted Stock Units | 100000 | $0.00 | 100,000.0000 | 0 | 9999.99% | 0.00% |